Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Tom Gordon who wrote (6214)	12/15/2000 12:53:12 PM
From: Montana Wildhack	Respond to of 14101

Tom, Agreed. I also agree with Osprey and am looking for a stronger close too. We'll see. Wolf

To: Tom Gordon who wrote (6214)	12/17/2000 5:22:39 PM
From: Montana Wildhack	Read Replies (1) \| Respond to of 14101

Tom, You mentioned downtrodden times. Most of the mail this weekend - although its amazingly quiet - has been about bottoms, probable lows, and future risks of other stocks and indexes, recession, Canadian impacts of US hard landing. (OT - I notice some parties are lobbying the Liberals not to put through the promised tax cuts due to timing of the stimulus. I just want to say I know where you park and I will key your cars). The Dow and S&P are down around 15% YTD and the NASDAQ is down close to 35%. The presidential conclusion did nothing to ease concerns and its a coin toss whether Greenspan has hit that soft landing or not. Now there are signs in Japan and Europe of a slowdown. But Dimethaid is 21st YTD in performance this year of the TSE300. It's 16th in Biotechs and the hottest stock on the TSE in the last month by a distance. Dimethaid investors aren't worried about new lows or eroding shareprice from announcements. We're waiting for a partner annoucement which we expect to have a another major positive impact. This time when we hit the teens - it'll be on solid accomplishments and realistic expectations. It's dead quiet on the board. This time though its quiet confidence. Not silent worrying. We'll get a good deal. Its a great product with some really fine selling features. Just the thing for hungry drug majors in Europe. And its fully approved right now. For those that are heavily margined - don't get swept up in the run. Sell some on the spike and take some profits. It will reduce your average cost significantly, your call point, and set you up to run through a possible quiet January/February. I suggest putting a sell in now good for the week at the price you want. Good luck everyone. Wolf